Newer ALK Inhibitor Tops Standard in NSCLC
MedPage Today,
TORONTO -- Progression-free survival (PFS) in advanced ALK-positive non-small cell lung cancer (NSCLC) improved by 50% in…
TORONTO -- Progression-free survival (PFS) in advanced ALK-positive non-small cell lung cancer (NSCLC) improved by 50% in…
January 08, 2016 The evolution of drug resistance in a patient with lung cancer was demonstrated in a case published in the New…
NEW YORK (GenomeWeb) – By examining and re-examining which gene mutations were present in a patient's tumor, clinicians were…
The use of drugs that target genetic mutations driving the growth of tumors has revolutionized treatment for several serious…